"10.1371_journal.pone.0047448","plos one","2013-01-23T00:00:00Z","Richard Puleston; George Bugg; Katja Hoschler; Justin Konje; James Thornton; Iain Stephenson; Puja Myles; Joanne Enstone; Glenda Augustine; Yvette Davis; Maria Zambon; Karl Nicholson; Jonathan Nguyen-Van-Tam","Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Clinical Sciences Building, City Hospital, Nottingham, United Kingdom; Nottingham University Hospitals National Health Service Trust, Queens Medical Centre, Nottingham, United Kingdom; Health Protection Agency, London, United Kingdom; Reproductive Sciences, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom; Division of Human Development, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom","Conceived and designed the experiments: RP JT JVT IS KN MZ PM. Performed the experiments: RP GB JT YD KH MZ JK. Analyzed the data: RP KN. Wrote the paper: RP JVT KN PM GA MZ KH JT JE.","Richard Puleston has received funding from Sanofi Pasteur to attend two influenza-related meetings. He will also be providing UNPAID consultancy advice to Novartis. Richard Puleston, Jonathan Nguyen Van Tam, Iain Stephenson and Karl Nicholson have received funding from GlaxoSmithKline to support virus isolation studies as a subsidiary (ongoing) component of this study. Joanne Enstone has received a one-off consultancy fee from GlaxoSmithKline and funding to attend an educational meeting from Sanofi Pasteur. Iain Stephenson has received funding to attend international scientific meetings (Novartis Vaccines), lecture and consultancy fees (Novartis, GSK and Baxter) and research funding from several pharmaceutical companies including Novartis Vaccines, GSK, Baxter Vaccines and Hoffman-La Roche. Maria Zambon and Katja Hoschler have been investigators of clinical trials sponsored by Novartis, Baxter, Sanofi Pasteur, and CSL Australia Ltd. Katja Hoschler has been sponsored by Sanofi Pasteur to take part and speak at one international meeting. Karl Nicholson has been an ad hoc consultant to GlaxoSmithKline, Merck, Sanofi Pasteur, and Novartis. He has received funding to speak at meetings organised by Novartis, Baxter, Berna Biotech, Esteves, and the European Scientific Working Group on Influenza, and H5 vaccines from Novartis to support an MRC-funded research project, and H1N1 vaccines from Baxter AG and GlaxoSmithKline to support an National Institute for Health Research-funded research project. Jonathan Nguyen Van Tam has received funding to attend influenza-related meetings, ad-hoc lecture and consultancy fees and research funding from several influenza antiviral drug and vaccine manufacturers (including both GlaxoSmithKline and Baxter AG), and is a former employee of SmithKline Beecham PLC (now GlaxoSmithKline), Roche Products Ltd, and Sanofi Pasteur MSD. The other authors have for themselves declared that no competing interests exist. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","01","Richard Puleston","RP",13,FALSE,7,7,2,9,TRUE,TRUE,FALSE,0,NA,FALSE
